Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447082 | 0.79 | L3MBTL1 (0.51) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL13701696 | 0.79 | LMNA (0.43) | KMT2ARAB9ALMNAMEN1IMPDH2 | |
| SCHEMBL29781378 | 0.78 | LMNA (0.49) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL17865779 | 0.78 | LMNA (0.58) | SMN1; SMN2LMNAPOLB | |
| SCHEMBL6918970 | 0.77 | L3MBTL1 (0.53) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL13875955 | 0.76 | POLB (0.44) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL28192657 | 0.76 | L3MBTL1 (0.55) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL12561259 | 0.75 | L3MBTL1 (0.59) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL12376722 | 0.75 | SMN1; SMN2 (0.59) | KMT2ARAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL13762120 | 0.74 | CYP2C9 (0.42) | KMT2ASMN1; SMN2LMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | KMT2A 3792/4885RAB9A 2708/4885L3MBTL1 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.